GLP-1 weight loss drugs

Ozempic maker sues Hims & Hers

Drug maker Novo Nordisk has filed a lawsuit against telehealth provider Hims and Hers over alleged copycat versions of its weight-loss and obesity medications.

People on GLP-1 drugs regain weight

A new University of Oxford review of research says many patients will return to their starting weight within two years of ending the treatment.